Business Wire

TX-SONAR

1.5.2024 15:01:34 CEST | Business Wire | Press release

Share
Lynne Doherty Joins Sonar as President of Field Operations

Sonar announced today that Lynne Doherty will join the organization as President of Field Operations. In her new role, Lynne will be responsible for driving revenue, and ensuring that Sonar's customers are successful in their pursuit of Clean Code. The leading provider of Clean Code solutions, Sonar accelerates mission-critical software development, reduces technical debt, and improves code quality and code security. Lynne will lead the company’s demand generation, global sales, solutions engineering, customer success, and customer support teams globally.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240501287633/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Lynne Doherty joins Sonar as President of Field Operations to accelerate revenue growth and global expansion. (Photo: Business Wire)

“Lynne has an outstanding track record of leading high-performing go-to-market organizations and driving positive business outcomes. We are excited that she is joining Sonar and believe she’s the ideal leader to help us in our next phase of growth,” said Tariq Shaukat, co-CEO of Sonar. “Having started her career as a Software Developer, she has a strong understanding of the value Sonar creates and a proven track record of working with customers to achieve that value.”

Lynne brings more than 20 years of sales leadership experience to Sonar, most recently as President, of Worldwide Field Operations at Sumo Logic, where she was focused on evolving the GTM organization for operational scale and speed. This included driving customer expansion and growing new logos, shifting the segmentation model, and starting a partner-first motion. Before that, she held various leadership roles at McAfee, where she drove over a billion dollars of revenue annually. In her time at McAfee, she led the team through several business evolutions, supported McAfee’s initial public offering, and multiple acquisitions.

“Sonar is a crucial tool for software developers and engineering teams that is especially necessary for AI-assisted code. With its Clean Code methodology, Sonar addresses a significant gap in the software development lifecycle, enhancing code quality and security hand-in-hand,” said Doherty. “Joining the Sonar team feels personal for me, in a sense, as I’m getting back to my roots as a developer, where I started my career. I’m thrilled to join the Sonar team and look forward to working alongside Tariq, Olivier, and the rest of the organization to deliver Clean Code.”

Before joining McAfee, Lynne held various sales and marketing leadership roles at Cisco, where she oversaw a team of more than 2,000 employees, and drove billions in revenue annually. While at Cisco, she also played a key role in the success of acquisitions of Duo Security, Umbrella, and Cloudlock. Lynne is an independent Director on the boards of CloudBees and the American Red Cross. She holds a B.S. in Mathematics and Computer Science from Temple University.

Over the last 15 years, Sonar has analyzed more than half-a-trillion lines of code across all industries and company sizes, resulting in a deep understanding of how code is written and managed. With that knowledge, Sonar has redefined what it means to write Clean Code in today’s software development life cycle, helping organizations accelerate mission-critical software development, manage proliferating risks, and build fast and reliable applications.

Sonar is currently hiring across a number of departments. You can learn more about joining the Sonar team here.

About Sonar

Sonar is a leading developer of open source solutions to help developers write Clean Code. Sonar’s solutions — SonarQube, SonarCloud, and SonarLint — support over 30 programming languages, frameworks, and infrastructure technologies. Trusted by more than 400,000 organizations globally to clean more than half a trillion lines of code, Sonar is integral to delivering higher quality, better-performing software.

To learn more about Sonar, please visit: https://www.sonarsource.com/products/all/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240501287633/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye